יחס שווי פעילות לרווח לפני ריבית, מסים ופחת Stereotaxis Corporation (STXS)

Stereotaxis, Inc. (STXS) develops robotic systems for catheter ablation, ensuring physician safety within the arrhythmia treatment segment. The historical price action based on the EV/EBITDA multiple is currently at 0.00. High business scalability is achieved through the sale of software and disposable instruments. The installed equipment base guarantees a regular inflow of funds, turning the supply of consumables into a stable cash cow.

Investors must eliminate speculative risks by assessing the real value of Stereotaxis, Inc. (STXS) assets. Current deliveries of Genesis systems establish an operational base, yet full-scale growth is expected following the launch of new catheters. Evaluating the business via EV/EBITDA trends compares the company's total enterprise value, including debt and taxes, against its operating profit. This indicator determines whether the asset is overvalued relative to its ability to generate cash flow.